CNTA
Centessa Pharmaceuticals plc
40.50
1 x 29.07
1 x 51.57
bid
ask
+
0.00
0.00%
1 @ 04:00 PM
40.68 +0.18 (0.45%)
| Ytd | 61.94% | |
| 1y | 208.45% |
day range
13.22
52 week range
40.56
| Open | Prev Close | 40.50 | Low | High | Mkt Cap | 6.27B | |||
| Vol | 0.00 | Avg Vol | 1.90M | EPS | -1.78 | P/E | N/A | Forward P/E | -22.75 |
| Beta | 1.12 | Short Ratio | 1.35 | Inst. Own | 96.93% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-14 | 50-d Avg | 39.77 | 200-d Avg | 29.97 | 1yr Est | 40.25 |
| Income Statement | |||
| Operating Expenses | 79.77M | ||
| Research and Development Expense | 59.89M | ||
| Selling, General and Administrative Expense | 19.88M | ||
| Operating Income | -79.77M | ||
| Interest Expense | 2.73M | ||
| Income Tax Expense | 850.00K | ||
| Net Income | -79.24M | ||
| Net Income Common Stock | -79.24M | ||
| Net Income Common Stock (USD) | -79.24M | ||
| Consolidated Income | -79.24M | ||
| Earnings per Basic Share | -0.52 | ||
| Earnings per Basic Share (USD) | -0.52 | ||
| Earnings per Diluted Share | -0.52 | ||
| Earning Before Interest & Taxes (EBIT) | -75.66M | ||
| Earning Before Interest & Taxes (USD) | -75.66M | ||
| Weighted Average Shares | 153.55M | ||
| Weighted Average Shares Diluted | 153.55M | ||
| Balance Sheet | |||
| Cash and Equivalents | 62.43M | ||
| Cash and Equivalents (USD) | 62.43M | ||
| Investments | 471.28M | ||
| Investments Current | 214.16M | ||
| Investments Non-Current | 257.12M | ||
| Current Assets | 348.68M | ||
| Property, Plant & Equipment Net | 10.52M | ||
| Total Assets | 641.76M | ||
| Total Debt | 117.81M | ||
| Current Liabilities | 36.57M | ||
| Debt Non-Current | 117.81M | ||
| Total Liabilities | 154.42M | ||
| Accumulated Retained Earnings (Deficit) | -1.27B | ||
| Accumulated Other Comprehensive Income | 1.41M | ||
| Shareholders Equity | 487.35M | ||
| Shareholders Equity (USD) | 487.35M | ||
| Assets Non-Current | 293.08M | ||
| Total Debt (USD) | 117.81M | ||
| Liabilities Non-Current | 117.84M | ||
| Trade and Non-Trade Payables | 10.66M | ||
| Tax Assets | 80.60M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 239.00K | ||
| Net Cash Flow from Financing | 30.47M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 1.13M | ||
| Issuance (Purchase) of Equity Shares | 34.12M | ||
| Net Cash Flow from Investing | 42.71M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 42.71M | ||
| Net Cash Flow from Operations | -72.22M | ||
| Effect of Exchange Rate Changes on Cash | 182.00K | ||
| Share Based Compensation | 10.57M | ||